Physician profile
Amanda Sutherland
NPI 1386870574
$380.40
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $324 · 2020: $56.08.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $80.79 | 2019-2020 | |
| Therapeuticsmd, INC. | $66.53 | 2019-2020 | |
| Roche Diagnostics Corporation | $47.22 | 2019 | |
| Lupin INC. | $36.16 | 2019 | |
| Daiichi Sankyo INC. | $34.65 | 2019 | |
| Abbvie INC. | $16.94 | 2019 | |
| Amag Pharmaceuticals, INC. | $16.92 | 2020 | |
| Amgen INC. | $16.29 | 2019 | |
| Allergan, INC. | $14.12 | 2019 | |
| Shire North American Group INC | $14.01 | 2019 | |
| Novo Nordisk INC | $13.33 | 2019 | |
| Avion Pharmaceuticals | $12.52 | 2019 | |
| Merck Sharp & Dohme LLC | $10.92 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Sutherland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.